 CAMBRIDGE, Mass.--BUSINESS WIRE--Seres Therapeutics, Inc. Nasdaq: MCRB, a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis UC. To access the conference call, please dial 844-277-9450 domestic or 336-525-7139 international and reference the conference ID numbe 